74
Participants
Start Date
July 31, 2016
Primary Completion Date
June 30, 2018
Study Completion Date
May 31, 2019
Tazemetostat
Tazemetostat (EPZ-6438) is a selective small molecule inhibitor of the histone-lysine methyltransferase EZH2 gene.
Memorial Sloan Kettering Cancer Center, New York
Institut Bergonie, Bordeaux
Mayo Clinic - Rochester, Rochester
CHRU de Lille, Lille
University of California, Los Angeles, Los Angeles
City of Hope National Medical Center, Los Angeles
University of California San Francisco, San Francisco
Institut Gustave Roussy, Villejuif
Massachusetts General Hospital, Boston
Dana-Farber Cancer Institute, Boston
University of Leicester & Leicester University Hospitals, Leicester
St. Bartholomew's Hospital, London
University College Hospital, London
Royal Marsden Hospital - Chelsea, London
University Hospital of South Manchester, Manchester
Royal Marsden Hospital - Surrey, Sutton
Lead Sponsor
Epizyme, Inc.
INDUSTRY